Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach
Elon H C van Dijk1, Thomas J van Rijssen2, Yousif Subhi3,4
1Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. ehcvandijk@lumc.nl.
Ophthalmology and Therapy
|April 13, 2020
Summary
Photodynamic therapy (PDT) with verteporfin effectively treats various chorioretinal diseases by targeting abnormal blood vessels. Recent protocol changes, like reduced verteporfin dosage, optimize treatment outcomes for conditions such as central serous chorioretinopathy.
Area of Science:
- Ophthalmology
- Medical Therapy
Background:
- Photodynamic therapy (PDT) with verteporfin (Visudyne®) is a standard treatment for inducing cell and tissue death, particularly for choroidal vascular abnormalities in ophthalmology.
- Initially used for neovascular age-related macular degeneration, PDT's applications have expanded to other chorioretinal conditions.
Purpose of the Study:
- To review the practical applications of photodynamic therapy (PDT) in treating various chorioretinal diseases.
- To discuss the evolution of PDT protocols and their impact on treatment outcomes.
Main Methods:
- Review of clinical studies and treatment protocols for photodynamic therapy (PDT).
- Analysis of PDT's role in managing neovascular age-related macular degeneration, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and choroidal hemangioma.
Main Results:
- PDT effectively targets and occludes abnormal choroidal vessels in various ophthalmological conditions.
- Optimized PDT protocols, including reduced verteporfin dosage and half-fluence, have improved treatment outcomes.
- PDT remains a valuable therapeutic option for a range of chorioretinal diseases.
Conclusions:
- Photodynamic therapy (PDT) is a versatile treatment for chorioretinal diseases, with evolving protocols enhancing its efficacy.
- The shift towards reduced treatment settings in PDT signifies an ongoing effort to refine its clinical application and patient outcomes.
